1246 / 1578
/
Study
# Pat / Tx
FU (months)
SBRT Dose
Local control
Ryu 2004
Henry Ford Hospital
49 / 61
6 – 24
1 x 10-16Gy
84% @ 1a
Gerszten 2007
Pittsburgh
49 / 65
Median 21
1 x 12.5 - 25Gy
90%
Chang 2007
M. D. Anderson
38 / -
Median 21
6 x 5Gy, 3 x 9Gy
84% @ 1a
Yamada 2008
MSKCC
93 / 103
Median 15
1 x 18 – 24Gy
90% @ 2a
Guckenberger 2009
Würzburg
14 / 16
Median 17
20 x 3Gy
89% @ 2a
Sahgal 2009
PMH / Stanford
14 / 23
Median 9
3 x 8Gy
78%
Balagamwana 2012
Cleveland Clinic
57 / 85
Median 5.4
1 x 15Gy
71% @ 1a
Garg 2012
M. D. Anderson
61 / 63
Median 20
1 x 16-24Gy
88 @ 1.5a
Heron 2012
Pittsburgh and Georgetown
228 / 348
Median 12
1 – 5 Fx
MF: 96% @ 2a
SF: 70% @ 2a
Schipani 2012
Henry Ford Hospital
124 / 165
Median 7
1 x 18Gy
Local tumor control after spine SBRT
ESTRO SBRT 2017 - Matthias Guckenberger
33
07.09.17
/
DOSIS: a multi-center phase II trial
ESTRO SBRT 2017 - Matthias Guckenberger
34
07.09.17
Prospective phase II trial
• 54 patients with 60 vertebral metastases
• No exclusion of patients with epidural disease
• Fractionated SBRT
• SBRT using SIB concept:
• 5 x 4 / 7Gy
• 10 x 3 / 4.85Gy
• Selection of patients with long OS expectancy